In short
Clinical trials investigating INSULIN DETEMIR are studying how it is used in diabetes care, mainly in adults with type 2 diabetes. These studies look at effectiveness, safety, and blood sugar control, often by comparing it with other basal insulin treatments. The main focus is on people who need insulin as part of treatment intensification.
Key points
- Clinical trial data for INSULIN DETEMIR shows it being used in adults with type 2 diabetes as part of a comparison with other daily basal insulin treatments. The study is Phase 3 and is designed to test blood sugar control in people already taking non-insulin glucose-lowering medicines. The main outcome is the change in HbA1c from the start of the study to week 52. The trial is authorised and plans to include 510 participants. The study also uses a non-inferiority goal, meaning it checks whether the new treatment is not meaningfully worse than the comparison treatment.
Trial overview
This clinical trial is studying type 2 diabetes in adults and is listed as Authorised.
The study is an interventional trial, which means researchers are giving treatments and then measuring the results.
Although the trial title focuses on once-weekly insulin icodec, the treatment list includes INSULIN DETEMIR as one of the daily basal insulin options used for comparison.
Study design and phase
This is a Phase 3 study, which is a later-stage trial usually done in a larger group of people to compare how well treatments work.
The planned enrollment is 510 participants.
The trial is designed to compare once-weekly insulin icodec with once-daily basal insulin analogues used at the investigator’s discretion in real-world clinical practice.
Who can participate
The study is for adults with type 2 diabetes.
The brief summary says participants are already using non-insulin glucose-lowering medications and need treatment intensification, which means their current treatment is not enough and a stronger plan is being tested.
No other detailed inclusion or exclusion rules are given in the source data, so only this target population can be confirmed here.
What is being measured
The main endpoint, or main result being measured, is the change in HbA1c from baseline week 0 to week 52.
HbA1c is a blood test that shows average blood sugar over time, so this outcome helps researchers see whether treatment improves long-term glucose control.
The study compares the difference in HbA1c change between once-weekly insulin icodec and once-daily basal insulin analogues, and it uses a non-inferiority limit of 0.3%.
Comparison treatments in the study
The intervention list includes several basal insulin products, and INSULIN DETEMIR appears as Levemir FlexPen and Levemir Penfill in the study materials.
Other comparison treatments listed in the trial include Lantus, Toujeo, Tresiba, and Awiqli, all given by subcutaneous injection, which means injection under the skin.
The source data does not describe the results of these comparisons yet, so the article can only report the study plan and endpoints, not final findings.
Patient-friendly explanation of key terms
Basal insulin means insulin used to help keep blood sugar steady through the day and night.
Treatment intensification means adding or changing treatment when current medicines are not enough.
Real-world clinical practice means the treatment is being studied in everyday care, not only in a highly controlled research setting.
Non-inferiority means the study is checking whether one treatment is not worse than another by more than a small allowed amount.